Neural Regeneration Research ›› 2023, Vol. 18 ›› Issue (9): 1954-1955.doi: 10.4103/1673-5374.367845

Previous Articles     Next Articles

Gene-modified neural progenitor cells for the treatment of neuropathic lysosomal storage diseases

Oriana Mandolfo, Brian W. Bigger*   

  1. Stem Cell and Neurotherapies, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
  • Online:2023-09-15 Published:2023-03-06
  • Contact: Brian W. Bigger, PhD, brian.bigger@manchester.ac.uk.
  • Supported by:
    Prof Brian W. Bigger acknowledges support from Innovate UK (Innovate Manchester Advanced Therapy Centre Hub – iMATCH).

Abstract: Lysosomal storage diseases: Lysosomal storage diseases (LSDs) are a family of about 70 disorders, with an overall incidence of 1:7000 live births. They are caused by dysfunctional lysosomal hydrolases, eventually leading to the accumulation of undegraded substrate into the lysosome. This results in a wide array of symptoms, which may include: the presence of dysmorphic features, cardio-respiratory disease, bone and joint disease, organomegaly, developmental delay and neurocognitive decline. The majority of these diseases have a neurological component and in the absence of treatment, death often occurs in the first decades of life, with the neurological complications drastically undermining the patient’s quality of life, as well as their families (Boustany, 2013).